• SENSIMED

  Led · Series C · Nov 2012

  Sensimed develops the SENSIMED Triggerfish, a non-invasive soft contact lens that provides continuous 24-hour intraocular pressure (IOP) profiles. The device centralizes 24-hour IOP profiles together with patient and treatment information on a registry and applies modeling and learning algorithms to identify pathological patterns and personalize treatment. Led by CEO Jean-Marc Wismer, the company focuses on using those profiles and analytics to differentiate indication and tailor therapy. Sensimed raised CHF17M in the first close of its Series C to fund near-term objectives. The capital will be used to finalize approvals in the US and China, expand commercialization beyond leading centers in about twenty countries, and continue a broad program of post-marketing application trials. The company also plans to implement and open its central registry to all users and to fund ongoing operations. Sensimed, founded in 2003 as an EPFL spin-off and based in Lausanne, develops the SENSIMED Triggerfish, a device for continuous monitoring of intraocular pressure, a key glaucoma risk factor. The Triggerfish is the company’s first approved product and is positioned for clinical and commercial rollout. The company received an additional CHF3.5m equity investment to support regulatory approval efforts in the US and Asian countries. Planned uses of the funds include commercialization in selected geographies, running post-marketing application trials and funding ongoing operations. Existing investors include Wellington Partners, Vinci Capital and BlueOcean Ventures, which previously closed the first part of the Series B. Strategic and private investors have also participated in the round.

• Anergis

  Led · Series A · Mar 2011

  Anergis is a clinical-stage biopharmaceutical company based in Epalinges, Switzerland, focused on developing innovative immunotherapies for allergic diseases. Its lead product, AllerT, targets patients allergic to birch pollen. The company plans to run a large Phase II multicenter trial of AllerT. It will also accelerate preclinical development of its broader product portfolio in new research laboratories. The CHF18m Series A financing is expected to cover the company’s financial requirements for the next two years. Anergis is led by CEO Vincent Charlon, PhD, and its board will be chaired by André J. Mueller. Representatives of the lead investors have joined the board to support development and oversight.

• Symetis

  Participated · Equity · Oct 2010

  Symetis is a Lausanne, Switzerland-based medical device company focused on transcatheter aortic valve implantation (TAVI) systems. Its lead product, Acurate TA™, is a self-aligning, nitinol stented tissue heart valve designed for trans-apical delivery, offering high positioning tolerance and ease of use. The company reported positive preliminary results from its first-in-man clinical study for Acurate TA™. Symetis is also developing Acurate TF™, a trans-femoral TAVI solution that is in pre-clinical validation and scheduled to enter clinical trials in 2011. The company raised CHF25M in equity financing to support commercial launch of its first product, clinical validation of Acurate TF™, and initiation of the US approval process. Board changes accompanied the financing, reflecting investor involvement in governance.

• Evolva

  Participated · Series B · Dec 2009

  Evolva Holding SA issued an announcement stating it had secured additional funding intended to support future growth. The notice was published as an EQS Group ad hoc release under the headline 'Evolva secures additional funding for future growth.' The release is dated 17‑May‑2021 and timed at 07:01 CET/CEST. The ad hoc announcement was made pursuant to Art. 53. The announcement does not specify the financing amount, instrument type, or any participating investors. It contains no operating metrics, past-round details, founding year, or location information. Evolva SA is a Swiss biotech that uses a genetic chemistry platform to develop small-molecule drugs. The company recently completed additional fundraising tied to a reverse merger that altered its corporate structure. Evolva added CHF16 million in additional Series B financing, bringing the round total to CHF44 million after an initial CHF28 million close in October. Backers named in the Series B include Wellington Partners, Aravis, Auriga Partners and Vinci Capital – Renaissance PME. The additional investment was part of Evolva’s reverse merger with Switzerland-listed Arpida Ltd. Separately, Evolva’s Indian subsidiary secured a CHF5 million funding commitment from Ventureast Trustee Company Pte Ltd. Evolva is a Basel-based Swiss biotech that develops clearly differentiated drug candidates and runs discovery partnerships that generate revenues. The company intends to progress its clinical compounds through phase II proof-of-concept trials over the next two to three years. To fund that work it will conduct a CHF 25m equity financing and says it has received positive feedback from existing and new investors. Evolva previously raised around $20m in venture capital from Novartis Venture, Aravis, Sunstone Capital and Dansk Innovationsinvestering. It currently employs 75 people, 30 of whom are located in Basel, and has operations in Denmark, the USA and India. The company has agreed to go public via a reverse merger with Arpida, which is listed on the Swiss stock exchange, and says the combined business will have promising growth prospects.

No current team members are available.